15-epi-lipoxin A4
metabolite15-epi-lipoxin A4 is an aspirin-triggered anti-inflammatory lipid mediator that limits plaque inflammation and platelet recruitment.
Pathway placement
Cascade stepPlaque inflammation
Confidencemedium
RationaleAspirin-triggered lipid mediator suppressing leukocyte and platelet activation.
Also acts inPlatelet activation
Druggability
Not assessed (no mapped human gene target).
Assay & specimen
Class-level default (no specific cleared assay)— generic method inferred from analyte class; confirm against a specific product insert before use.
Specimen
Serum, plasma or urine
Collection tube
Serum separator (gold/red-top, SST) · Lithium heparin (green-top) · Sterile urine container
Method / principle
LC-MS/MS (targeted metabolomics) or enzymatic colorimetric where available
Reagent / substrate
Stable-isotope-labeled internal standard (MS); or enzyme-coupled Trinder reagent
Platform
LC-MS/MS; some automated chemistry
Turnaround · availability
Send-out / research · Specialized / research
Literature evidence(1)
- Antiinflammatory effects of aspirin in ACS: relevant to its cardiocoronary actions?Thrombosis and haemostasis · 2015 · PMID 26085050 · doi
Clinical trials(1)
- The Effect of Ticagrelor on 15-Epi-Lipoxin A4 and InflammationNCT02626169 · PHASE4 · WITHDRAWN · Clopidogrel, Ticagrelor